KR102513120B1 - 중추신경계(cns)에 단백질을 전달하기 위한 조작된 기생충 - Google Patents

중추신경계(cns)에 단백질을 전달하기 위한 조작된 기생충 Download PDF

Info

Publication number
KR102513120B1
KR102513120B1 KR1020197001560A KR20197001560A KR102513120B1 KR 102513120 B1 KR102513120 B1 KR 102513120B1 KR 1020197001560 A KR1020197001560 A KR 1020197001560A KR 20197001560 A KR20197001560 A KR 20197001560A KR 102513120 B1 KR102513120 B1 KR 102513120B1
Authority
KR
South Korea
Prior art keywords
toxoplasma
protein
nucleic acid
promoter
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197001560A
Other languages
English (en)
Korean (ko)
Other versions
KR20190021339A (ko
Inventor
오데드 레차비
샤하르 브라차
리아치 샤이너
Original Assignee
라모트 앳 텔-아비브 유니버시티 리미티드
더 유니버시티 코트 오브 더 유니버시티 오브 글래스고우
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라모트 앳 텔-아비브 유니버시티 리미티드, 더 유니버시티 코트 오브 더 유니버시티 오브 글래스고우 filed Critical 라모트 앳 텔-아비브 유니버시티 리미티드
Publication of KR20190021339A publication Critical patent/KR20190021339A/ko
Application granted granted Critical
Publication of KR102513120B1 publication Critical patent/KR102513120B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/45—Toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01015—Aspartoacylase (3.5.1.15)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01046—Galactosylceramidase (3.2.1.46)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/05—Carbon-nitrogen ligases with glutamine as amido-N-donor (6.3.5)
    • C12Y603/05005—Carbamoyl-phosphate synthase (glutamine-hydrolysing) (6.3.5.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020197001560A 2016-06-29 2017-06-29 중추신경계(cns)에 단백질을 전달하기 위한 조작된 기생충 Active KR102513120B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662355898P 2016-06-29 2016-06-29
US62/355,898 2016-06-29
PCT/IL2017/050731 WO2018002938A1 (en) 2016-06-29 2017-06-29 Engineered parasites for delivering protein to the central nervous system (cns)

Publications (2)

Publication Number Publication Date
KR20190021339A KR20190021339A (ko) 2019-03-05
KR102513120B1 true KR102513120B1 (ko) 2023-03-27

Family

ID=60786743

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197001560A Active KR102513120B1 (ko) 2016-06-29 2017-06-29 중추신경계(cns)에 단백질을 전달하기 위한 조작된 기생충

Country Status (8)

Country Link
US (3) US11260081B2 (enExample)
EP (1) EP3478301A4 (enExample)
JP (3) JP7148415B2 (enExample)
KR (1) KR102513120B1 (enExample)
CN (1) CN109757100A (enExample)
AU (1) AU2017289886A1 (enExample)
CA (1) CA3028334A1 (enExample)
WO (1) WO2018002938A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3478301A4 (en) 2016-06-29 2020-04-22 Ramot at Tel-Aviv University Ltd. Manipulated parasites for the delivery of protein to the central nervous system (CNS)
AU2019261646A1 (en) * 2018-04-27 2020-11-12 Spacecraft Seven, Llc Gene therapy for CNS degeneration
CN109369796A (zh) * 2018-09-27 2019-02-22 华中农业大学 一种检测羊弓形虫IgG抗体的酶联免疫方法
CN110117609B (zh) * 2019-05-20 2023-06-02 安徽农业大学 一种真菌基因敲除双荧光筛选方法
WO2020240024A1 (en) * 2019-05-29 2020-12-03 Université De Tours Toxoplasma platform for treating cancer
BR112021024636A2 (pt) * 2019-06-10 2022-01-18 Infectious Disease Res Inst Métodos e composições de replicons de astrovírus
US12257320B2 (en) 2020-03-11 2025-03-25 Massachusetts Eye And Ear Infirmary Gene therapy for NMNAT1-associated retinal degeneration
US11497801B2 (en) * 2021-02-19 2022-11-15 Sherryll Layton Compositions and methods of enhancing immune responses
KR102561980B1 (ko) * 2021-03-16 2023-08-01 한양대학교 에리카산학협력단 톡소포자충 gra9 단백질 또는 상기 단백질을 암호화하는 유전자를 유효성분으로 포함하는, 염증성 질환 예방 또는 치료용 약학적 조성물
CN114524869B (zh) * 2022-01-25 2023-06-09 华中农业大学 弓形虫微线体蛋白MIC17a及其应用
KR102834734B1 (ko) * 2022-04-28 2025-07-16 경희대학교 산학협력단 톡소포자충의 항원 rop4를 포함하는 재조합 백시니아 바이러스 백신
WO2024064918A2 (en) * 2022-09-23 2024-03-28 Novome Biotechnologies, Inc. Recombinant fusion polypeptides for secreting soluble, heterologous cargo
WO2025026988A1 (en) * 2023-07-28 2025-02-06 Theranexus Mutated tfeb for treating lysosomal disorders
EP4560316A1 (en) * 2023-11-23 2025-05-28 Biokit Research & Development S.L.U. Antigenic regions for the detection of anti-toxoplasma gondii igm antibodies
CN117925759B (zh) * 2024-01-23 2024-07-02 通化康元生物科技有限公司 林蛙多肽制剂及其在食品和化妆品中的应用
WO2025235741A1 (en) * 2024-05-09 2025-11-13 Grann Pharmaceuticals Inc. Compositions and methods for modulating mecp2 activity
CN119925428B (zh) * 2025-04-07 2025-07-11 天津捷昂康生物科技发展有限公司 一种树突状细胞在预防和/或治疗脱髓鞘疾病中的应用
CN120424771B (zh) * 2025-07-08 2025-10-17 华中农业大学 弓形虫mic19基因敲除虫株及其构建方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046321A1 (en) * 2014-09-25 2016-03-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating cancer and infectious diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693325A (en) * 1994-03-15 1997-12-02 Molecumetics, Ltd. Peptide vaccines and methods relating thereto
US8293224B2 (en) 2000-02-07 2012-10-23 Trustees Of Dartmouth College Attenuated uracil auxotroph of an apicomplexan and use thereof
US20030096260A1 (en) * 2001-10-09 2003-05-22 Zhenhua Miao Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
JP2006518184A (ja) * 2002-09-20 2006-08-10 アクゾ・ノベル・エヌ・ベー 弱毒寄生虫生ワクチン
US9757440B2 (en) * 2007-10-29 2017-09-12 Trustees Of Dartmouth College Method for treating cancer with Toxoplasma gondii vaccine
EP3478301A4 (en) 2016-06-29 2020-04-22 Ramot at Tel-Aviv University Ltd. Manipulated parasites for the delivery of protein to the central nervous system (CNS)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046321A1 (en) * 2014-09-25 2016-03-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating cancer and infectious diseases

Also Published As

Publication number Publication date
KR20190021339A (ko) 2019-03-05
JP2019525744A (ja) 2019-09-12
US20220160790A1 (en) 2022-05-26
JP7148415B2 (ja) 2022-10-05
CN109757100A (zh) 2019-05-14
WO2018002938A1 (en) 2018-01-04
AU2017289886A1 (en) 2019-01-24
JP2022184996A (ja) 2022-12-13
JP2024112982A (ja) 2024-08-21
US12070476B2 (en) 2024-08-27
CA3028334A1 (en) 2018-01-04
EP3478301A4 (en) 2020-04-22
US11260081B2 (en) 2022-03-01
JP7497397B2 (ja) 2024-06-10
US20250057892A1 (en) 2025-02-20
US20200121731A1 (en) 2020-04-23
JP7748681B2 (ja) 2025-10-03
EP3478301A1 (en) 2019-05-08

Similar Documents

Publication Publication Date Title
KR102513120B1 (ko) 중추신경계(cns)에 단백질을 전달하기 위한 조작된 기생충
US12006508B2 (en) Methods and products for expressing proteins in cells
US11286480B2 (en) Methods and compositions for sequence specific antimicrobials
IL267334B2 (en) Enhanced gene transfer mediated by the hAT transposon family and related compositions, systems and methods
KR101961332B1 (ko) Cas9 단백질 및 가이드 RNA를 포함하는 안질환 치료용 약학 조성물
US20220280569A1 (en) ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS
KR101753069B1 (ko) 헤마글루티닌-뉴라미니다아제와 f 단백질을 과발현하는 중간엽줄기세포 및 그 용도
EP2872635A2 (en) Genome surgery with paired, permeant endonuclease excision
Tuszynski Prospects for Gene Therapy for Central Nervous System Disease

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190117

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200626

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220706

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230104

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230320

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230321

End annual number: 3

Start annual number: 1

PG1601 Publication of registration